Citizens Jmp Issues Positive Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

Key Points

• Citizens Jmp raised its target on BioCryst to $28 and maintained a "market outperform" rating, implying roughly a 220% upside; the analyst consensus remains a "Moderate Buy" with an average target near $20.70 (nine Buys, three Holds).
• Q1 results were mixed: revenue beat estimates at $156.4M (driven by ORLADEYO sales of $148.3M, +11% y/y) and FY26 guidance of $635–$660M, but the company reported a large GAAP EPS loss of ($2.98) vs. a $0.06 estimate and a negative ROE, which pressured sentiment.
• Insider and institutional activity: Director Alane P. Barnes sold 150,000 shares (27% of her position) in March, while about 85.9% of the stock is held by hedge funds and other institutions.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its target price raised by research analysts at Citizens Jmp from $25.00 to $28.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a "market outperform" rating on the biotechnology company's stock. Citizens Jmp's target price would suggest a potential upside of 220.55% from the company's previous close.

A number of other equities research analysts also recently commented on the company. Weiss Ratings raised BioCryst Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a report on Wednesday, March 4th. Royal Bank Of Canada decreased their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a research note on Friday, January 30th. Evercore started coverage on BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They set an "outperform" rating and a $17.00 price target on the stock. Needham & Company LLC decreased their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, Wedbush decreased their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an "outperform" rating on the stock in a research note on Thursday. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $20.70.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock traded down $0.10 during midday trading on Thursday, reaching $8.74. The company's stock had a trading volume of 2,678,377 shares, compared to its average volume of 5,071,250. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The stock's 50 day simple moving average is $9.05 and its 200 day simple moving average is $7.81. The firm has a market capitalization of $2.22 billion, a PE ratio of 7.25 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same period last year, the business posted $0.20 EPS. BioCryst Pharmaceuticals's revenue was up 7.5% compared to the same quarter last year. Equities analysts predict that BioCryst Pharmaceuticals will post 0.26 earnings per share for the current year.

Insider Activity

In related news, insider Alane P. Barnes sold 150,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the transaction, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. The trade was a 27.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. Larson Financial Group LLC grew its stake in BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 3,267 shares during the period. Focus Partners Wealth purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $77,000. Farther Finance Advisors LLC grew its stake in BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 8,109 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 2,115 shares during the period. Finally, Vestmark Advisory Solutions Inc. purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $81,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals News Summary

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Strong ORLADEYO sales: Q1 ORLADEYO net revenue was $148.3M, up 11% y/y (and +21% y/y on a comparable basis excluding Europe), supporting top-line momentum for BioCryst. Q1 Financial Results
• Positive Sentiment: Licensing deal for European sale: BioCryst licensed a drug candidate for European commercialization, which can accelerate market access and monetize assets outside its core U.S. franchise. Licensing Announcement
• Positive Sentiment: Analyst support remains: Wedbush cut its price target to $21 but kept an "Outperform" rating (still implying >100% upside), and Needham trimmed its PT to $16 while maintaining a "Buy" rating — both actions signal continued analyst confidence despite the pullbacks. Wedbush Coverage Needham Coverage
• Neutral Sentiment: Revenue beat but guidance roughly in line: Q1 revenue came in above consensus (~$156.4M vs. ~$151.1M est), and the company set FY26 revenue guidance of $635–$660M (close to consensus), leaving overall topline outlook largely consistent with expectations. Revenue and Estimates
• Neutral Sentiment: Earnings call highlighted pipeline progress and new risk disclosures: Management discussed growth drivers and emerging risks on the Q1 call — useful context for investors but not immediately decisive on valuation. Earnings Call Summary
• Negative Sentiment: Large GAAP EPS swing / headline miss: The company reported a GAAP EPS loss (headlined as a large negative number in some releases), creating confusion versus other reports of a small loss — the apparent significant EPS miss and negative ROE raise concerns about one‑time items and accounting that pressured sentiment. Q1 Press Release / Slides Market Reaction & Details

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.